meta|Evidence - COVID-19
click on circles to display study description...
baricitinib (n=4148) vs. standard of care (n=4008)
randomized controlled trial some concerns about risk of bias
baricitinib 4 mg once daily
baricitinib 4 mg once daily by mouth for 10 days or until discharge if sooner
usual standard of care alone
COVID 19 all comers
open-label
convalescent plasma treatment (n=4) vs. standard of care (n=8)
randomized controlled trial low risk of bias
Convalescent plasma
Standard of care
COVID 19 all comers
Open-label.
Italy.
Study not published yet. Results and risk of bias assessment were extracted from Axfors C. et al meta-analysis https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06829-7?s=09.
leflunomide (n=26) vs. interferon (n=24)
randomized controlled trial some concerns about risk of bias
Leflunomide
leflunomide (50 mgevery 12 hours, 3 consecutive times, orally; then 20 mg onc edaily for 8 days; a total course of 10 days) plus nebulized interferon alpha 2a (IFN-α-2a; 3 million IU each time, adding2 mL of sterilized water, atomization inhalation twice daily for10 days)
Interferon alpha 2a
IFN-α-2a, 3 million IU each time, twice daily for 10 days.
COVID 19 all comers
(1) age 18–70 years with a diagnosis of COVID-19 conforming to Chinese guidelines (2) hospitalized for prolonged postsymptomatic viral shedding; (3) able to orally take medication; (4) if female, not pregnant; and (5) effective contraception for 7 days after taking the last medication.
Open-label.
Single center, Renmin Hospital of Wuhan University, Wuhan, China.
tocilizumab (n=161) vs. placebo (n=81)
randomized controlled trial low risk of bias
Tocilizumab
Tocilizumab single dose (8 mg per kilogram of body weight administered intravenously, not to exceed 800 mg) plus standard of care.
Placebo
COVID 19 all comers
Age > 18 and < 80 years old, Male or female gender, Confirmed SARS-CoV-2 infection by NP swab PCR, Admitted to non-ICU level care at MGH WITH evidence of severe COVID-19 (at least 2 of the following): Fever > 38C, Pulmonary infiltrates on chest X ray, Need for supplemental O2 to maintain saturation > 92% AND at least 1 of the following: Ferritin > 500 ng/ml, CRP > 50 mg/L, LDH >250 U/L, D-dimer > 1000 ng/mL.
Double-blind.
7 Boston hospitals, United States.
tocilizumab (n=136) vs. standard of care (n=134)
randomized controlled trial risk of bias NA
experimental: intervention early administration of tocilizumab associated with hydroxychloroquine and azithromycin
tocilizumab 162 mg sc x 2 doses tocilizumab 162mg sc x 2 doses at 12 hours (day 1)hydroxychloroquine 400 mg / 12h v.o. day 1 followed by 200 mg / 12h v.o. for 6 days (7 days in total)azithromycin 500 mg / day v.o. for 3 days
hydroxychloroquine and azithromycin
hydroxychloroquine 400 mg / 12h v.o. day 1 followed by 200 mg / 12h v.o. for 6 days (7 days in total)azithromycin 500 mg / day v.o. for 3 days
COVID 19 all comers
open-label
Spain
pilot, randomized, multicenter, open-label clinical trial
powered by vis.js Network